广康生化 reported revenue of ¥0.38B for the period ended 2026-06-30, -4.2% year on year. Net income was ¥0.00B, a 1.1% net margin on a 21.0% gross margin. The largest revenue line is 原药 at 68% of the total. Free cash flow for the period was ¥-0.06B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.38B | -4.2% |
| Gross profit | ¥0.08B | — |
| Operating income | ¥0.00B | — |
| Net income | ¥0.00B | -85.5% |
| Gross margin | 21.0% | Net margin 1.1% |
| Revenue Q/Q | +38.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| 原药 | ¥0.26B | 67.9% |
| 制剂 | ¥0.11B | 28.3% |
| 中间体 | ¥0.01B | 3.4% |
| 其他(补充) | ¥0.00B | 0.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.30B | 79.0% |
| R&D | ¥0.02B | 4.6% |
| SG&A | ¥0.05B | 12.4% |
| Tax & other | ¥-0.00B | -0.4% |
| Item | Amount |
|---|---|
| Total assets | ¥2.22B |
| Total liabilities | ¥0.86B |
| Shareholders' equity | ¥1.36B |
| Equity / assets | 61.4% |
| Operating cash flow | ¥-0.02B |
| Capital expenditure | ¥0.05B |
| Free cash flow | ¥-0.06B |
| Cash conversion (OCF / net income) | -1745% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
电声股份 ・ 斯迪克 ・ 天迈科技 ・ 久量股份 ・ 华辰装备 ・ 中科海讯 ・ 铂科新材 ・ 易天股份 ・ 泰林生物 ・ 中富电路 ・ 玉禾田 ・ 艾可蓝
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies